La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Amgen Gestion
Gestion contrôle des critères 3/4
Le PDG Amgen's est Bob Bradway, nommé en May2010, a un mandat de 14.25 ans. La rémunération annuelle totale est $ 22.64M, composée du salaire de 7.9% et des bonus 92.1%, y compris les actions et options de la société. détient directement 0.12% des actions de la société, d'une valeur de $ 206.50M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.9 ans et 7.7 ans.
Informations clés
Bob Bradway
Directeur général
US$22.6m
Rémunération totale
| Pourcentage du salaire du PDG | 7.9% |
| Durée du mandat du directeur général | 14.3yrs |
| Propriété du PDG | 0.1% |
| Durée moyenne d'occupation des postes de direction | 4.7yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.8yrs |
Mises à jour récentes de la gestion
Recent updates
Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Sep 26Amgen: Growth Is Still A Better Choice
Aug 28Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09
Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors
Dec 13Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?
Oct 23Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Sep 22Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?
Sep 04Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13
Aug 05Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$23m | US$2m | US$7b |
| Sep 30 2023 | n/a | n/a | US$8b |
| Jun 30 2023 | n/a | n/a | US$8b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$21m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$7b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$7b |
| Dec 31 2020 | US$20m | US$2m | US$7b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$20m | US$2m | US$8b |
| Sep 30 2019 | n/a | n/a | US$8b |
| Jun 30 2019 | n/a | n/a | US$8b |
| Mar 31 2019 | n/a | n/a | US$8b |
| Dec 31 2018 | US$19m | US$2m | US$8b |
| Sep 30 2018 | n/a | n/a | US$2b |
| Jun 30 2018 | n/a | n/a | US$2b |
| Mar 31 2018 | n/a | n/a | US$2b |
| Dec 31 2017 | US$17m | US$2m | US$2b |
Rémunération vs marché: La rémunération totale de Bob ($USD 22.64M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 13.17M ).
Rémunération et revenus: La rémunération de Bob a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Bob Bradway (61 yo)
14.3yrs
Titularisation
US$22,643,650
Compensation
Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 14.3yrs | US$22.64m | 0.12% $ 196.6m | |
| Executive VP & CFO | 4.7yrs | US$7.57m | 0.0046% $ 7.7m | |
| Executive Vice President of Operations | 8.2yrs | US$7.21m | 0.011% $ 19.2m | |
| Executive VP & CTO | less than a year | US$7.90m | 0.0094% $ 15.8m | |
| Executive Vice President of Global Commercial Operations | 6yrs | US$8.24m | 0.0075% $ 12.5m | |
| Chief Accounting Officer & VP of Finance | 1.1yrs | pas de données | 0.00056% $ 941.4k | |
| Executive VP of Research & Development and Chief Scientific Officer | less than a year | pas de données | pas de données | |
| Vice President of Investor Relations | no data | pas de données | pas de données | |
| Executive VP | 9.2yrs | US$7.24m | 0.0046% $ 7.8m | |
| Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer | 4.7yrs | pas de données | 0.0013% $ 2.2m | |
| Senior Vice President of Global Marketing & Access | less than a year | pas de données | pas de données | |
| Senior Vice President of Human Resources | 2.7yrs | pas de données | 0.0012% $ 2.0m |
4.7yrs
Durée moyenne de l'emploi
56.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de AMGN est considérée comme expérimentée (ancienneté moyenne 4.9 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 12.9yrs | US$22.64m | 0.12% $ 196.6m | |
| Lead Independent Director | 11.8yrs | US$419.92k | 0.0013% $ 2.2m | |
| Co-Chair of Scientific Advisory Board | no data | US$292.01k | pas de données | |
| Co-Chair of the Scientific Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 4.2yrs | US$359.92k | 0.000080% $ 134.5k | |
| Independent Director | 7.6yrs | US$369.92k | 0.00023% $ 386.7k | |
| Independent Director | 10.9yrs | US$379.92k | 0.0023% $ 3.9m | |
| Independent Director | 7.9yrs | US$360.29k | 0.000080% $ 134.5k | |
| Independent Director | 6.3yrs | US$359.92k | 0.00015% $ 252.2k | |
| Independent Director | 12.3yrs | US$339.92k | 0.00051% $ 857.4k | |
| Independent Director | 6.8yrs | US$359.92k | 0.0012% $ 2.1m | |
| Independent Director | 3.2yrs | US$366.47k | 0.00017% $ 285.8k |
7.8yrs
Durée moyenne de l'emploi
68yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de AMGN sont considérés comme expérimentés (ancienneté moyenne 7.7 ans).